LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 213
- Registration Number
- NCT02668692
- Locations
- 🇯🇵
Medical Corporation Bikyukai Kokubu Dermatology, Kitami-shi, Hokkaido, Japan
Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 91
- Registration Number
- NCT02664805
- Locations
- 🇩🇪
Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie, Berlin, Germany
A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 233
- Registration Number
- NCT02650505
- Locations
- 🇺🇸
TKL Research Inc., Fair Lawn, New Jersey, United States
Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study
Completed
- Conditions
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 603
- Registration Number
- NCT02636101
- Locations
- 🇷🇺
Municipal out-patient clinic 7, Saratov, Russian Federation
An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 55
- Registration Number
- NCT02627989
Dermatopharmacokinetic Trial of LEO 80185 Gel
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT02605057
- Locations
- 🇯🇵
Shinanokai Shinanozaka Clinic, Tokyo, Japan
Preferences & Treatment Satisfaction Drivers in Rosacea Patients
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 206
- Registration Number
- NCT02602470
Biological Effects of LEO 43204 in Actinic Keratosis
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT02600598
- Locations
- 🇺🇸
Beacon Clinical Research, LLC, Quincy, Massachusetts, United States
🇺🇸Long Island Skin Cancer and Dermatology Surgery, Smithtown, New York, United States
The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 440
- Registration Number
- NCT02594436
- Locations
- 🇬🇷
Office Based Physician, Athens, Peristeri, Greece
An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 10
- Registration Number
- NCT02577185
- Locations
- 🇩🇰
Hud- og Kønssygdomme, Aarhus Universitetshospital, Aarhus, Denmark
🇩🇰Hud- og allergiafdeling, Gentofte Hospital, Gentofte, Denmark
© Copyright 2024. All Rights Reserved by MedPath